Last: | $18.10 |
---|---|
Change Percent: | -2.19% |
Open: | $17.72 |
Close: | $18.10 |
High: | $18.11 |
Low: | $17.34 |
Volume: | 1,601,334 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$18.1 | $17.72 | $18.1 | $18.11 | $17.34 | 1,601,334 | 04-24-2024 |
$17.34 | $17.45 | $17.34 | $18.27 | $17.3 | 1,783,630 | 04-23-2024 |
$17.59 | $16.78 | $17.59 | $17.68 | $16.775 | 1,963,738 | 04-22-2024 |
$16.07 | $16.56 | $16.07 | $16.79 | $15.81 | 1,855,067 | 04-19-2024 |
$16.67 | $16.34 | $16.67 | $16.84 | $16.05 | 1,580,580 | 04-18-2024 |
$16.39 | $16.23 | $16.39 | $16.88 | $15.89 | 1,544,588 | 04-17-2024 |
$16.16 | $16.84 | $16.16 | $16.8899 | $16.035 | 2,121,926 | 04-16-2024 |
$17.06 | $18.34 | $17.06 | $18.45 | $16.94 | 2,701,134 | 04-15-2024 |
$18.26 | $18.42 | $18.26 | $18.575 | $17.96 | 1,308,053 | 04-12-2024 |
$18.68 | $19.35 | $18.68 | $19.41 | $18.32 | 1,113,315 | 04-11-2024 |
$19.11 | $18.29 | $19.11 | $19.21 | $18.02 | 1,854,087 | 04-10-2024 |
$19.2 | $18.75 | $19.2 | $19.86 | $18.75 | 1,950,743 | 04-09-2024 |
$18.66 | $17.61 | $18.66 | $18.795 | $17.59 | 2,216,708 | 04-08-2024 |
$17.63 | $18.05 | $17.63 | $18.295 | $17.57 | 2,483,787 | 04-05-2024 |
$18.15 | $19.86 | $18.15 | $20.12 | $18.13 | 3,649,400 | 04-04-2024 |
$19.7 | $20.76 | $19.7 | $21.68 | $19.53 | 3,183,779 | 04-03-2024 |
$20.79 | $22.25 | $20.79 | $22.57 | $19.62 | 6,454,821 | 04-02-2024 |
$20.25 | $20.7 | $20.25 | $20.7 | $19.36 | 2,065,103 | 04-01-2024 |
$20.63 | $18.2 | $20.63 | $20.755 | $18.13 | 5,569,146 | 03-29-2024 |
$20.63 | $18.2 | $20.63 | $20.755 | $18.13 | 5,569,146 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / ...
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal™ in detection and quantification of residual disease in early-stage breast can...